4C-MenB Vaccine for Gonorrhea
Trial Summary
What is the purpose of this trial?
This is a double-blind randomized controlled trial to test whether the group B meningitis vaccine 4 component Neisseria meningitidis serogroup B vaccine (BEXSEROTM) (4C-MenB), trade name Bexsero™), currently approved for use by the United States Food and Drug Administration (FDA) and recommended by the Centers for Disease Control and Prevention (CDC) for protection from Neisseria meningitidis infections, also protects from Neisseria gonorrhoeae infection using controlled human experimental infection to test protection. The information the investigator learn by doing this study may also help to develop a vaccine that protects individuals from having gonorrhea infection. The study population will consist of male participants \> 18 and \< 36 years old, living in central North Carolina, in general good health without a history of 4C-MenB vaccination. Approximately 120-140 participants will be enrolled. Participants will receive 2 doses of vaccine (2 doses of 4C-MenB or 2 comparator vaccines- seasonal influenza and tetanus/diptheria booster) as intramuscular injections, and then one intraurethral challenge with Neisseria gonorrhoeae. Following the challenge, participants will cross-over and receive two doses of vaccines not received prior to challenge (2 doses of 4CMenB or the 2 comparator vaccines- seasonal influenza and tetanus/diptheria booster) All participants receive all vaccinations by the end of the study and all vaccines used in this study are licensed and FDA-approved.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you must stop all current medications, but certain medications are not allowed with the antibiotics used in the study. You should avoid medications like warfarin, probenecid, and some others listed in the trial details.
What data supports the effectiveness of the 4C-MenB vaccine (Bexsero) for treating gonorrhea?
Is the 4C-MenB (Bexsero) vaccine safe for humans?
The 4C-MenB (Bexsero) vaccine has been used safely in people aged 10-25 years, with safety data collected from reports in the Vaccine Adverse Event Reporting System (VAERS) between 2015 and 2018. It has been used in response to outbreaks and is recommended for those at increased risk of meningococcal disease.678910
How is the 4C-MenB vaccine different from other treatments for gonorrhea?
The 4C-MenB vaccine, originally developed to protect against meningococcal disease, is unique because it contains multiple components that trigger an immune response, potentially offering protection against gonorrhea, a condition with limited vaccine options. This approach is novel as it repurposes a vaccine designed for a different bacterial infection to address gonorrhea.6781011
Eligibility Criteria
This trial is for healthy males aged 18-35 in central North Carolina who haven't been vaccinated against Neisseria meningitidis group B. Participants must consent to avoid sexual activity during certain phases, not have a history of severe reactions to antibiotics or vaccines, and be able to attend all study visits.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Vaccination
Participants receive two doses of vaccines (either BEXSERO™ or control vaccines) prior to the bacterial challenge phase
Neisseria gonorrhoeae Challenge
Participants receive a suspension containing N. gonorrhoeae and are monitored for development of urethritis
Post-Challenge Vaccination
Participants receive two doses of vaccines not received prior to the challenge (either BEXSERO™ or control vaccines)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 4C-MenB (Vaccine)
4C-MenB is already approved in European Union, United States for the following indications:
- Invasive meningococcal disease caused by serogroup B
- Invasive meningococcal disease caused by serogroup B in adolescents and young adults aged 10 through 25 years